News | August 20, 2023
Lupin receives approval from USFDA for Bromfenac Ophthalmic
Bromfenac Ophthalmic Solution 0.09% (RLD Bromday) had estimated annual sales of USD 11 million in the U.S. (IQVIA MAT June 2023).
Bromfenac Ophthalmic Solution 0.09% (RLD Bromday) had estimated annual sales of USD 11 million in the U.S. (IQVIA MAT June 2023).
Glenmark's current portfolio consists of 184 products authorized for distribution in the U.S. marketplace
Lupin actively contributes to alleviating the burden of COPD for patients across the nation
Doxycycline Hyclate Delayed-Release Tablets USP (RLD Doryx ) had estimated annual sales of USD 9 million in the U.S. (IQVIA MAT June 2023).
This is the 166th ANDA out of Eugia Pharma Speciality Group facilities
Fluocinolone Acetonide Oil (RLD Derma-Smoothe/FS®) had estimated annual sales of USD 10 million in the U.S. (IQVIA MAT June 2023)
The product is being launched in August 2023
Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.
Norgestrel and Ethinyl Estradiol Tablets USP (RLD Lo/Ovral-28) had an estimated annual sale of USD 34 million in the U.S. (IQVIA MAT Mar 2023)
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
Subscribe To Our Newsletter & Stay Updated
